Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double …
TX Zhao, M Kostapanos, C Griffiths, EL Arbon… - BMJ open, 2018 - bmjopen.bmj.com
Introduction Inflammation and dysregulated immune responses play a crucial role in
atherosclerosis, underlying ischaemic heart disease (IHD) and acute coronary syndromes …
atherosclerosis, underlying ischaemic heart disease (IHD) and acute coronary syndromes …
Regulatory T-cell response to low-dose interleukin-2 in ischemic heart disease
TX Zhao, RS Sriranjan, ZK Tuong, Y Lu… - NEJM …, 2022 - evidence.nejm.org
Background Atherosclerosis is a chronic inflammatory disease of the artery wall. Regulatory
T cells (Tregs) limit inflammation and promote tissue healing. Low doses of interleukin (IL)-2 …
T cells (Tregs) limit inflammation and promote tissue healing. Low doses of interleukin (IL)-2 …
[HTML][HTML] A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO)
WN Hayes, E Laing, R Brown, L Silsby, L Smith… - Kidney International, 2024 - Elsevier
Acute electrolyte and acid-base imbalance is experienced by many children following
kidney transplant. This is partly because doctors give very large volumes of artificial fluids to …
kidney transplant. This is partly because doctors give very large volumes of artificial fluids to …
Convalescent plasma donors show enhanced cross‐reactive neutralizing antibody response to antigenic variants of SARS‐CoV‐2 following immunization
Background The therapeutic benefit of convalescent plasma (CP) therapy to treat COVID‐19
may derive from neutralizing antibodies (nAbs) to SARS‐CoV‐2. To investigate the effects of …
may derive from neutralizing antibodies (nAbs) to SARS‐CoV‐2. To investigate the effects of …
Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable …
PJ Cacciottolo, MS Kostapanos, EH Sancho… - BMJ open, 2021 - bmjopen.bmj.com
Introduction Elevated low-density lipoprotein cholesterol (LDL-C) is a strong independent
risk predictor of cardiovascular (CV) events, while interventions to reduce it remain the only …
risk predictor of cardiovascular (CV) events, while interventions to reduce it remain the only …
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured …
CM McEniery, M Fisk, K Miles, F Kaloyirou, A Hubsch… - Trials, 2020 - Springer
Abstract Objectives Primary objective To determine whether chemoprophylaxis with
hydroxychloroquine versus placebo increases time to contracting coronavirus disease 2019 …
hydroxychloroquine versus placebo increases time to contracting coronavirus disease 2019 …
THE EFFECTS OF ALIROCUMAB VERSUS EZETIMIBE ON TOP OF STATINS ON VASCULAR INFLAMMATION AND FUNCTION
PJ Cacciottolo, M Kostapanos, A Hubsch… - Journal of the American …, 2021 - jacc.org
Background Low-density lipoprotein cholesterol (LDL) is a strong independent risk predictor
of cardiovascular (CV) events. The lowest threshold beyond which reduction of LDL confers …
of cardiovascular (CV) events. The lowest threshold beyond which reduction of LDL confers …
[PDF][PDF] LETTER Open Access
CM McEniery, M Fisk, K Miles, F Kaloyirou… - 2020 - trialsjournal.biomedcentral.com
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC)
to prevent covid-19 infection in frontline h Page 1 LETTER Open Access …
to prevent covid-19 infection in frontline h Page 1 LETTER Open Access …
Correction to: ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers …
CM McEniery, M Fisk, K Miles, F Kaloyirou, A Hubsch… - Trials, 2020 - ncbi.nlm.nih.gov
Reference 1. McEniery, et al. ChemoPROphyLaxIs with hydroxychloroquine For covId-19
infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers …
infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers …
CORRECTION Open Access
CM McEniery, M Fisk, K Miles, F Kaloyirou, A Hubsch… - trialsjournal.biomedcentral.com
Reference 1. McEniery, et al. ChemoPROphyLaxIs with hydroxychloroquine For covId-19
infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers …
infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers …